Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic partnership between its PPD clinical research business and Datavant Inc., the US-based health data connectivity platform, to integrate and analyze real-world data (RWD) across clinical trial operations. The collaboration will enhance randomized trials with RWD enrichment, leverage PPD CorEvitas Clinical Registries, and optimize PPD Evidera solutions through Datavant’s privacy-preserving tokenization technology.

Partnership Structure

Element	Detail
Technology Provider	Thermo Fisher Scientific Inc. (NYSE: TMO) – PPD clinical research business
Data Connectivity Partner	Datavant Inc. (US-based health data platform)
Collaboration Focus	Real-world data (RWD) integration and analysis
Applications	RWD-enriched randomized trials; CorEvitas registries; Evidera solutions
Datavant Network	350+ RWD partners; 80,000+ US hospitals and clinics

Technology Integration & Capabilities

Datavant Capability	PPD Application	Strategic Value
Tokenization & Linking	Patient-level data connectivity across disparate sources	De-identified dataset integration without privacy compromise
Privacy Preservation	Secure EMR retrieval for customized RWD generation	Regulatory compliance (HIPAA, GDPR); patient trust maintenance
Network Scale	80,000+ US healthcare facilities	Comprehensive real-world evidence capture; generalizability enhancement
RWD Enrichment	Randomized clinical trial augmentation	External control arms; long-term safety monitoring; efficacy validation

Strategic Rationale & Market Context

Factor	Industry Analysis
Real-World Evidence (RWE) Demand	FDA, EMA, NMPA increasingly accepting RWE for regulatory decisions; post-market requirements expanding; RWD integration critical for accelerated approvals
Clinical Trial Efficiency	RWD enrichment reduces trial costs and timelines; external comparators enable smaller control arms; post-trial follow-up without patient burden
PPD Competitive Positioning	Thermo Fisher’s CRO scale + Datavant connectivity creates differentiated RWD-enabled trial offering vs. IQVIA, Syneos, Parexel
CorEvitas & Evidera Synergy	Autoimmune and rare disease registries (CorEvitas) + health economics expertise (Evidera) enhanced by Datavant’s longitudinal data linking
Privacy-First Design	Tokenization technology addresses data governance concerns; enables cross-border RWD utilization for global trials

Implementation & Commercial Outlook

Priority	Execution Plan	Timeline
Technology Integration	Datavant APIs embedded in PPD trial management systems	2026
Pilot Programs	RWD-enriched trials in oncology, immunology, rare disease	2026-2027
Regulatory Engagement	FDA/EMA RWE framework alignment; qualification pathways	Ongoing
Global Expansion	International RWD partner network expansion (EU, Asia-Pacific)	2027-2028
Commercialization	Premium RWD-enabled trial offerings; outcome-based contracts	2027+

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Thermo Fisher PPD and Datavant partnership execution, RWD integration in clinical trials, and real-world evidence regulatory acceptance. Actual results may differ due to data privacy regulation changes, healthcare system interoperability challenges, and competitive responses from IQVIA and other CROs.-Fineline Info & Tech

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Partnership Structure

Technology Integration & Capabilities

Strategic Rationale & Market Context

Implementation & Commercial Outlook

You Missed

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Partnership Structure

Technology Integration & Capabilities

Strategic Rationale & Market Context

Implementation & Commercial Outlook

Related Post

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

You Missed

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer